Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies that underscore major advances in molecular diagnostics and precision ...

The patent holder in that case, Myriad Genetics, had patented a test on the BRCA1 and BRCA2 genes. The test shows mutations that reveal which women are more susceptible to breast and ovarian cancer.

SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and ...

Yesterday, the U.S. Supreme Court issued its anxiously awaited decision in Association for Molecular Pathology et al. v. Myriad Genetics, Inc., No. 12-398 (U.S. June 13, 2013). The Court addressed ...

A company that helped pioneer genetic tests used to diagnose and treat disease lost more than 40% of its value on Wednesday, after U.S. regulators raised questions about whether a DNA test that ...